By March 2024, patent database analyses confirmed Bertozzi was named on over 100 granted U.S. patents across nearly 300 global filings.
By March 21, 2024, comprehensive analyses of global patent databases documented that Carolyn Bertozzi was named as an inventor on more than 100 granted U.S. patents, spanning nearly 300 patent filings across international jurisdictions. This milestone underscored her status as one of the most prolific chemist-inventors of her generation, a distinction relatively rare among academic scientists, let alone Nobel laureates.
This body of patented work spanned the full arc of her career, from early biomaterials research in the late 1990s and early 2000s, through her foundational bioorthogonal chemistry patents filed throughout the 2000s, to later innovations in glycoscience, immunotherapy, and diagnostic technologies developed at both UC Berkeley and Stanford University.
The scale of her patent portfolio reflects not only her scientific creativity but also her sustained commitment to translational research—ensuring that her laboratory's fundamental discoveries could be developed into practical technologies benefiting medicine and biotechnology. Several of her patents underpinned companies she co-founded, including Redwood Bioscience, Lycia Therapeutics, and other biotechnology ventures applying bioorthogonal chemistry to real-world therapeutic and diagnostic challenges.
This documented patent milestone, reported in analyses published in early 2024, situates Bertozzi among an elite group of scientist-inventors whose combined contributions to basic science and applied technology have reshaped entire fields, complementing her Nobel Prize in Chemistry with a robust legacy of tangible technological innovation.